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Abstract
Background: The aim of this study was to describe data on epidemiology, ventilatory management, and outcome
of acute respiratory distress syndrome (ARDS) in immunocompromised patients.
Methods: We performed a post hoc analysis on the cohort of immunocompromised patients enrolled in the Large
Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG SAFE) study.
The LUNG SAFE study was an international, prospective study including hypoxemic patients in 459 ICUs from 50
countries across 5 continents.
Results: Of 2813 patients with ARDS, 584 (20.8%) were immunocompromised, 38.9% of whom had an unspecified
cause. Pneumonia, nonpulmonary sepsis, and noncardiogenic shock were their most common risk factors for ARDS.
Hospital mortality was higher in immunocompromised than in immunocompetent patients (52.4% vs 36.2%;
p < 0.0001), despite similar severity of ARDS. Decisions regarding limiting life-sustaining measures were significantly
more frequent in immunocompromised patients (27.1% vs 18.6%; p < 0.0001). Use of noninvasive ventilation (NIV) as
first-line treatment was higher in immunocompromised patients (20.9% vs 15.9%; p = 0.0048), and immunodeficiency
remained independently associated with the use of NIV after adjustment for confounders. Forty-eight percent of the
patients treated with NIV were intubated, and their mortality was not different from that of the patients invasively
ventilated ab initio.
Conclusions: Immunosuppression is frequent in patients with ARDS, and infections are the main risk factors for ARDS
in these immunocompromised patients. Their management differs from that of immunocompetent patients,
particularly the greater use of NIV as first-line ventilation strategy. Compared with immunocompetent subjects, they
have higher mortality regardless of ARDS severity as well as a higher frequency of limitation of life-sustaining measures.
Nonetheless, nearly half of these patients survive to hospital discharge.
Trial registration: ClinicalTrials.gov, NCT02010073. Registered on 12 December 2013.
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Background
In recent decades, significant advances in the manage-
ment of immunocompromised patients have led to im-
proved survival rates [1–3]. Hence, intensive care unit
(ICU) admission and invasive life-sustaining treatments
are offered with increasing frequency to these patients
[3, 4]. However, several studies show that the prognosis
of critically ill patients with active malignancies or im-
munodeficiency remains poor, especially when the cause
of ICU admission is acute respiratory distress syndrome
(ARDS) requiring invasive mechanical ventilation (IMV)
[5–11]. Data about incidence, causes, management, and
outcomes of ARDS in immunocompromised patients are
scarce. The best ventilatory strategy in this population is
still uncertain, and available literature data on the role of
noninvasive ventilation (NIV) are conflicting [12–22].
Recently, researchers in the Large Observational Study
to Understand the Global Impact of Severe Acute
Respiratory Failure (LUNG SAFE study) investigated the
incidence, management, and clinical outcomes in pa-
tients with acute hypoxemic respiratory failure (AHRF)
requiring ventilatory support, with a specific focus on
ARDS [23]. This aim of this post hoc subgroup analysis
was to describe the epidemiology, clinical characteristics,
ventilatory management (with particular attention to the
use of NIV), and outcomes of ARDS in the subset of pa-
tients with clinically significant immunodeficiency.
Methods
LUNG SAFE: patients, study design, and data collection
LUNG-SAFE was an international, multicenter, pro-
spective observational cohort study conducted in a 459
ICUs worldwide. During 4 consecutive weeks in the win-
ter of 2014 (February–March 2014 in the Northern
Hemisphere and June–August 2014 in the Southern
Hemisphere), participating ICUs enrolled patients
undergoing IMV or NIV. Participating ICUs obtained
ethics committee approval and either patient consent or
waiver of consent as per local guidelines. National coordi-
nators, site investigators, and endorsing societies are listed
in Additional file 1. Exclusion criteria were age < 16 years
or lack of informed consent when required. Patients were
screened daily for AHRF, defined as follows: (1) ratio of
partial pressure of arterial oxygen to fraction of in-
spired oxygen (PaO2/FiO2) ≤ 300 mmHg while receiv-
ing IMV or NIV with positive end-expiratory pressure
(PEEP) ≥ 5 cmH2O and (2) new radiological pulmonary
parenchymal abnormalities. In patients with AHRF, a more
detailed set of data was collected to determine whether
they met the Berlin definition criteria for ARDS. Data on
comorbidities, etiology of AHRF, and risk factors for ARDS
were recorded. Data on arterial blood gases, ventilatory
support, use of adjunctive therapies (e.g., prone position-
ing, extracorporeal membrane oxygenation, neuromuscular
blockade), severity of ARDS, and other organ involvement
by modified nonpulmonary Sequential Organ Failure
Assessment (SOFA) score [24] were collected on selected
days. The following clinical endpoints were assessed: ICU
and hospital survival, censored at 90 days after enrollment;
duration of mechanical ventilation; changes in ARDS se-
verity; and decision to withhold or withdraw life-sustaining
therapies. A full description of the methods of the LUNG
SAFE study, including the full study protocol, case report
form (CRF), sample size, and quality control, can be found
in the original study paper [23].
Immunocompromised patient cohort and definitions
We defined “immunocompromised” patients as all pa-
tients with at least one of the following conditions listed
in the LUNG SAFE CRF: (1) immunosuppression (defined
as viral immunosuppression, neoplastic disease, immuno-
suppressive drugs including steroids, chemotherapy, or
congenital immunosuppression), (2) active hematologic
malignancy (i.e., still requiring treatment), and (3) active
neoplasm (i.e., a neoplasm that has not been resected, still
requires treatment, or with metastasis). Patients without
these conditions were classified as “controls.” For the pur-
poses of this analysis, the study population was restricted
to the subset of patients fulfilling ARDS criteria on day 1
or 2 following the onset of AHRF.
In regard to management, patients were subdivided in
three ventilation subgroups: (1) IMV, defined as patients
invasively ventilated from day 1, independently of the
type of support received after the eventual extubation;
(2) NIV, defined as patients treated exclusively with NIV
from day 1 to study exit (i.e., ICU discharge or death);
and (3) NIV failure, defined as patients initially treated
with NIV and subsequently intubated during the study
period. The term NIV encompassed all forms of NIV
modes and interfaces (including continuous positive
airway pressure). ARDS severity was assessed from the
first to the second day from ARDS onset, according to
the Berlin definition criteria: mild (PaO2/FiO2 201–
300 mmHg), moderate (PaO2/FiO2 101–200 mmHg),
and severe (PaO2/FiO2 ≤ 100 mmHg). Changes in ARDS
severity were evaluated in patients staying in the ICU for
at least 2 days, and they were classified into four
categories: (1) no change, (2) worsening (shift to a more
severe category), (3) improvement (shift to a less severe
category), and (4) resolution. Duration of invasive venti-
lation was computed as the number of days that the pa-
tient required IMV up to day 28. Survival was evaluated
at ICU and hospital discharge or at day 90, whichever
event occurred first.
Statistical analysis
Continuous variables were expressed as mean (SD) or
median (IQR), and categorical variables were presented
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as count and percent. No assumptions were made for
missing data, which were rare [23]. To assess differences
between groups, we used Student’s t test or the
Wilcoxon rank-sum test (according normality distribu-
tion of data) for continuous variables and the χ2 or
Fisher’s exact test (according sample size) for proportions.
We used analysis of variance or the Kruskal-Wallis test
(as appropriate) and the χ2 test (or Fisher’s exact test) to
assess differences among the NIV, NIV failure, and IMV
groups. The Bonferroni correction was applied to deter-
mine significance in the setting of multiple comparisons.
To evaluate factors associated with the use of NIV, we
applied a multivariable logistic regression model, and the
independent predictors (demographic characteristics, co-
morbidities, ARDS risk factors, and clinical parameters
concerning the illness severity of ARDS onset) were
identified through a stepwise regression approach. This
approach combines forward and backward selection
methods (combined with a significance level of 0.05 for
both entry and retention) in an iterative procedure to
select predictors in the final multivariable model. This
approach was also applied to identify factors associated
with hospital mortality in immunocompromised pa-
tients. In this case, the stepwise approach also evaluated
as possible predictors ventilator setting variables mea-
sured at ARDS onset.
Survival analysis was performed according to the
Kaplan-Meier method. We assumed that patients dis-
charged alive from the hospital before 90 days were alive
on day 90. The log-rank test was used to compare sur-
vival curves among groups.
All p values were two-sided, and values less than 0.05
were considered significant. Statistical analyses were car-
ried out with R version 3.3.3 (R Project for Statistical
Computing; https://www.r-project.org/) and SAS version
9.4 software (SAS Institute, Cary, NC, USA).
Results
Baseline patient characteristics
A total of 459 ICUs from 50 countries enrolled patients
in the LUNG SAFE study. Among 12,906 mechanically
ventilated patients, 4499 had AHRF, and of these, 2813
fulfilled the Berlin criteria for ARDS on day 1 or 2.
Among ARDS patients, 584 (20.8%) were immunocom-
promised (Fig. 1). Of these, 232 (39.7%) had an active
neoplasm and 138 (23.6%) had a hematologic malig-
nancy, whereas the causes of immunosuppression were
not specified in 38.7%. Table 1 shows baseline characteris-
tics of immunocompromised and control patients. Im-
munocompromised subjects were younger than controls
(60.3 vs 61.6 years; p = 0.0163) and had a lower body mass
index (BMI) (25.5 ± 5.8 vs 28.1 ± 9.2 kg/m2; p < 0.0001).
They had a lower prevalence of chronic obstructive
pulmonary disease, diabetes mellitus, and heart failure
(New York Heart Association classes III–IV) and a higher
incidence of pneumonia, pulmonary vasculitis, and non-
cardiogenic shock. Among immunocompromised pa-
tients, 28.6% had mild, 46.4% moderate, and 25.0% severe
ARDS, and the most common risk factors for ARDS were
pneumonia (70.5%), nonpulmonary sepsis (16.1%), and
noncardiogenic shock (10.3%). Nonpulmonary SOFA
score at day 1 and ARDS severity were similar between
immunocompromised and controls. Additional file 2 com-
pares comorbidities, ARDS severity, and nonpulmonary
SOFA score in the three ventilation subgroups (IMV, NIV,
and NIV failure) among immunocompromised patients.
Mean patient age in the NIV subgroup was older than in
the other two subgroups, and the difference between NIV
and IMV was statistically significant (65.2 vs 59.7 years;
p = 0.0045). Comorbidities and PaO2/FiO2 were not differ-
ent among the subgroups. There was a marked difference
in the mean nonpulmonary SOFA score, which was sig-
nificantly higher in IMV than in NIV (7.0 ± 3.9 vs 3.7 ± 3.1;
p < 0.0001) and NIV failure subgroups (7.0 ± 3.9 vs
5.3 ± 3.6; p = 0.0023).
Fig. 1 Flow diagram of the study. Flow diagram showing the
distribution of patients included in this analysis dataset, according to
ventilation subgroup. AHRF acute hypoxemic respiratory failure, ARDS
Acute respiratory distress syndrome, IMV Patients invasively ventilated
from day 1, independently of the type of support received after the
eventual extubation, NIV Patients treated exclusively with noninvasive
ventilation, from day 1 to study exit, independently of outcome,
NIV failure Patients initially treated with noninvasive ventilation and
subsequently intubated during the study period
Cortegiani et al. Critical Care  (2018) 22:157 Page 3 of 15
Table 1 Patients characteristics in immunocompetent (Control) and immunocompromised (Study) groups
Patients characteristics Control
(n = 2229)
Study
(n = 584)
p Value
Sex, age, and BMI
Women, n (%) 837 (37.6) 247 (42.3) 0.0360
Age, yr, mean ± SD 61.6 ± 17.1 60.3 ± 15.5 0.0163
BMI (kg/m2), mean ± SD 28.1 ± 9.2 25.5 ± 5.8 < 0.0001
Comorbidities, n (%)
COPD 522 (23.4) 85 (14.6) < 0.0001
Diabetes mellitus 523 (23.5) 90 (15.4) < 0.0001
Hearth failure (NYHA classes III-IV) 260 (11.7) 30 (5.1) < 0.0001
Chronic renal failure 222 (10.0) 64 (11.0) 0.4769
Chronic liver failure (Child-Pugh class C) 91 (4.1) 21 (3.6) 0.5924
Home ventilation 52 (2.3) 7 (1.2) 0.0886
ARDS risk factors, n (%)
Pneumonia 1271 (57.0) 412 (70.5) < 0.0001
Pulmonary contusion 86 (3.9) 1 (0.2) < 0.0001
Pulmonary vasculitis 7 (0.3) 7 (1.2) 0.0140
Major trauma 111 (5.0) 1 (0.2) < 0.0001
Aspiration of gastric contents 348 (15.6) 54 (9.2) < 0.0001
Pancreatitis 54 (2.4) 5 (0.9) 0.0187
Noncardiogenic shock 154 (6.9) 60 (10.3) 0.0063
Drug overdose 46 (2.1) 5 (0.9) 0.0515
Severe burns 8 (0.4) 0 (0.0) 0.2183
Inhalational injury 58 (2.6) 12 (2.1) 0.4498
Drowning 1 (0.04) 1 (0.2) 0.3722
Nonpulmonary sepsis 361 (16.2) 94 (16.1) 0.9535
Blood transfusions 82 (3.7) 29 (5.0) 0.1550
Other risk factors 61 (2.7) 12 (2.2) 0.4925
None 194 (8.7) 40 (6.8) 0.1487
Cause of immunosuppression, n (%)
Known (hematologic and/or active neoplasm) – 357 (61.1) –
Unknown – 227 (38.9) –
Illness severity at ARDS onset
Nonpulmonary SOFA scorea, mean ± SD
First day of ARDS 6.2 ± 4.1 6.5 ± 4.0 0.1150
Second day of ARDS 6.3 ± 4.3 6.7 ± 4.3 0.0283
PaO2/FiO2 ratio, mmHg, mean ± SD 161.3 ± 67.1 157.2 ± 67.9 0.1660
Mild ARDSb, n (%) 666 (29.9) 167 (28.6) 0.5455
Moderate ARDSb, n (%) 1067 (47.9) 271 (46.4) 0.5280
Severe ARDSb, n (%) 496 (22.3) 146 (25.0) 0.1590
Abbreviations: BMI Body mass index, ARDS Acute respiratory distress syndrome, COPD Chronic obstructive pulmonary disease, NYHA New York Heart Association,
SOFA Sequential Organ Failure Assessment, PaO2/FiO2 Ratio of partial pressure of arterial oxygen to fraction of inspired oxygen
Note: Bold p values represent a statistically significant difference between the two groups
aNonpulmonary SOFA score adjusted for missing values
bSeverity of ARDS was evaluated according to the Berlin definition
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Type of ventilatory support, ventilator setting, and
adjunctive measure/therapies
Figure 1 summarizes the type of ventilatory support in
enrolled patients. On day 1 of ARDS, IMV was the most
frequent type of ventilatory approach in both groups;
however, NIV use as first-line treatment was significantly
more frequent in immunocompromised than in im-
munocompetent patients (20.9% vs 15.9%; p = 0.0044).
The proportion of patients remaining on NIV from day
1 to study exit (NIV subgroup) was similar, whereas the
incidence of NIV failure was significantly higher in im-
munocompromised patients (10.1% vs 6.4%; p = 0.0021).
A multivariable logistic regression model revealed that,
adjusting on confounders, immunodeficiency was inde-
pendently associated with the use of NIV (OR, 1.567;
95% CI, 1.217–2.017; p = 0.0005). Other factors associ-
ated with NIV are shown in Additional file 3.
Additional file 4 compares the ventilator settings on
the first day of ARDS between immunocompromised
and control patients: FiO2 and respiratory rate and PEEP
were statistically significantly higher in immunocom-
promised patients, but the difference for PEEP was not
clinically relevant. There was no difference in tidal
volume, peak and plateau pressures, and the proportion
of patients with spontaneous ventilation. No significant dif-
ferences were observed in adjunctive therapies, except for
a significantly higher use of continuous neuromuscular
blocking agents in the immunocompromised group (22.6%
vs 18.5%; p = 0.0266) (Additional file 5). Additional file 6
describes ventilator settings in immunocompromised and
immunocompetent (control) patients, stratified by the type
of ventilator support (IMV, NIV, NIV failure).
Clinical endpoints
Table 2 compares selected clinical endpoints in im-
munocompromised and control patients. Hospital mor-
tality and ICU mortality were significantly higher in
immunocompromised subjects (respectively, 52.4% vs
36.2%, p < 0.0001; and 45.5% vs 31.3, p < 0.0001),
whereas there was no difference in duration of mechan-
ical ventilation and changes in ARDS severity. Survival
curves for hospital (or 90-day) mortality are shown in
Fig. 2. The decision to withhold and/or withdraw
life-sustaining measures was significantly more frequent
in immunocompromised patients (Table 2). The same
clinical endpoints were also analyzed in the cohort of
Table 2 Clinical endpoints in immunocompetent (Control) and immunocompromised (Study) patients
Clinical endpoints Control
(n = 2229)
Study
(n = 584)
p Value
IMV during ICU stay, n (%) 1874 (84.1) 462 (79.1) 0.0044
NIV success during ICU stay, n (%) 212 (9.5) 63 (10.8) 0.3551
NIV failure during ICU stay, n (%) 143 (6.4) 59 (10.1) 0.0021
Duration of mechanical ventilation, d, median (Q1–Q3) 8.0 (4.0–15.0) 8.0 (4.0–14.0) 0.4213
Progression/regression of ARDSa, n (%) 0.5613
No change 824 (41.7) 201 (39.6)
Progression 214 (10.8) 55 (10.8)
Regression 422 (21.3) 123 (24.2)
Resolution 518 (26.2) 129 (25.4)
Limitation of life-sustaining measures, n (%)
Decision to withhold life-sustaining measures 415 (18.6) 158 (27.1) < 0.0001
Decision to withdraw life-sustaining measures 356 (16.0) 129 (22.1) 0.0005
Decision to withhold or withdraw life-sustaining measures 507 (22.7) 195 (33.4) < 0.0001
ICU mortalityb, n (%) 698 (31.3) 266 (45.5) < 0.0001
Hospital mortalityc, n (%)
All patients 804 (36.2) 304 (52.4) < 0.0001
Patients with limitations of life-sustaining measuresd 419 (82.6) 173 (88.7) 0.0473
Abbreviations: ARDS Acute respiratory distress syndrome, IMV Invasive mechanical ventilation, ICU Intensive care unit, NIV Noninvasive mechanical ventilation,
Q1 First quartile, Q3 Third quartile
aChange in ARDS severity (according Berlin definition) was not evaluable for 327 pients (251 immunocompetent and 76 immunocompromised patients)
bMortality is defined as mortality at ICU discharge or at the 90th day in the ICU after onset of acute hypoxemic respiratory failure, whichever event occurred first
cMortality is defined as mortality at hospital discharge or at the 90th day in the hospital after onset of acute hypoxemic respiratory failure, whichever event
occurred first
dMortality assessed on patients with a decision to withhold or withdraw life-sustaining measures
Note: Bold p values represent a statistically significant difference between the two groups
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immunocompromised patients according to the ventila-
tion subgroup (Table 3). Duration of mechanical ventila-
tion and decisions of limitation (both withholding and
withdrawal) of life-sustaining measures were not different
among the subgroups. ICU mortality was significantly
lower in NIV patients than in the IMV (28.6% vs
46.3%; p = 0.0078) and NIV failure (28.6% vs 57.6%;
p = 0.0012) subgroups. Of the NIV patients who died, 68%
had a limitation of life-sustaining measures. The incidence
of NIV failure was 48%. ICU and hospital mortality of pa-
tients with NIV failure were significantly higher than those
of patients managed exclusively with NIV (respectively,
57.6% vs 28.6%, p = 0.012; and 62.7 vs 39.7%, p = 0.011),
whereas they did not differ from those of IMV patients.
Survival curves for hospital (or 90-day) mortality of im-
munocompromised patients stratified by ARDS severity
and by ventilation subgroups are shown in Additional files 7
and 8, respectively. In a multivariable logistic regression
model, factors independently associated with hospital mor-
tality in immunocompromised patients were higher non-
pulmonary SOFA score (OR, 1.079; 95% CI, 1.026–1.134;
p = 0.0032), higher peak inspiratory pressure level
(OR, 1.028; 95% CI, 1.007–1.051; p = 0.0097), lower PaO2/
FiO2 ratio (OR, 0.995; 95% CI, 0.992–0.998; p = 0.0022),
lower degree of improvement in PaO2/FiO2 ratio between
day 1 and day 2 of ARDS (OR, 0.996; 95% CI, 0.993–0.999;
p= 0.0058), and lower BMI (OR, 0.944; 95% CI, 0.91–0.98;
p= 0.0023) (Additional file 9). According to the investigators’
clinical judgment, in immunocompromised patients,
the most common main factor leading to death in
ICU was respiratory failure (51.5%), followed by car-
diovascular failure. In contrast, cardiovascular failure
was the most common factor in the control group
(Additional file 10).
Additional file 11 describes patient characteristics and
clinical endpoints in immunocompetent (control) pa-
tients according to type of ventilator support. Because
the lack of a precise definition of the cause of immuno-
suppression in a relevant proportion of patients may
affect the strength of our findings, we compared baseline
patient characteristics and clinical outcomes in patients
with a “known” cause of immunosuppression (i.e., those
with active hematologic malignancy or active neoplasm)
and in patients with an unspecified (“unknown”) cause
of immunosuppression (i.e., those indicated in the CRF
with the generic term immunosuppression). The results of
this analysis are reported in Additional file 12. Briefly, pa-
tients with an unspecified cause of immunosuppression
were significantly younger (55.7 ± 15.6 vs 63.1 ± 14.8 years;
p < 0.0001) and had lower hospital mortality (41.6% vs
59.3%; p < 0.0001) and fewer limitations of life-sustaining
measures (27.3% vs 37.3%; p = 0.013).
Fig. 2 Kaplan-Meier curve for hospital survival. Mortality was defined as mortality at hospital discharge or at 90 days after onset of acute hypoxemic
respiratory failure, whichever event occurred first. We assumed that patients discharged alive from the hospital before 90 days were alive on day 90.
Note: The number of patients at risk reported at the bottom of the figure is referred to as the end of the corresponding day
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Discussion
The main findings of this analysis can be summarized as
follows: immunosuppression is frequent in ARDS pa-
tients; causes of ARDS in immunocompromised patients
are mainly related to infection; immunocompromised
patients are more likely to receive NIV as first-line venti-
latory treatment; and the outcome of ARDS is worse and
limitation of life-sustaining measures is more frequent in
immunocompromised patients. Among the 2813 ARDS
patients included in the LUNG SAFE study, one-fifth
were immunocompromised, and 62.7% of them had an
active malignancy. In line with recent literature [18, 21],
a diagnosis of active malignancy is considered as a cause of
immunosuppression, owing to the negative effects on im-
mune function of anticancer treatments and of the malig-
nancy itself. All other causes of immune deficiency were
identified by the generic variable “immunosuppression.”
To the best of our knowledge, this was the first prospect-
ive, multicenter study conducted on a large cohort of
immunocompromised patients with a diagnosis of ARDS
according to Berlin definition criteria [25], whereas
previous studies relied on the definition of the
American-European Consensus Conference on ARDS [26].
As expected, ARDS in immunocompromised patients was
associated mainly with an infectious cause. Pneumonia,
noncardiogenic shock, and pulmonary vasculitis were sig-
nificantly more frequent in immunocompromised patients,
whereas other risk factors for ARDS were more frequently
represented in the control group.
Immunocompromised subjects had a significantly
higher ICU and hospital mortality, despite similar ARDS
severity and nonpulmonary SOFA score. Another subana-
lysis of the same database confirmed that active neoplasm,
hematologic malignancies, and immunosuppression are
independently associated with increased mortality [27]. In
addition, the higher frequency of limitation of life-sustain-
ing measures (probably as a result of perceived futility)
may have contributed to the increased mortality of im-
munocompromised patients [27]. This is in line with the
results of Laffey et al., who found that immunosuppres-
sion and cancer were among the factors associated with
increased likelihood of limitation of life-sustaining
therapies [27].
Hospital mortality of our patients was lower than that
(64%) reported by Azoulay et al. in a large retrospective
analysis of 1004 patients with cancer and ARDS admit-
ted to the ICU over a period of 21 years [28]. In that
study, mortality did drop from 89% in the 1990–1995
period to 52% in the 2006–2011 period, matching the
mortality rate of our population.
Table 3 Clinical endpoints in immunocompromised (Study) patients according to ventilation subgroup
Clinical endpoints IMV
(n = 462)
NIV
(n = 63)
NIV failure
(n = 59)
p Value
Duration of mechanical ventilation, d, median (Q1–Q3) 8.0 (4.0–14.0) – 8.0 (5.0–15.0) 0.4352
Progression/regression of ARDSa, n (%)
No change 161 (40.1) 18 (32.1) 22 (43.1) 0.4449
Progression 43 (10.7) 5 (8.9) 7 (13.7) 0.7199
Regression 103 (25.7) 4 (7.1)b 16 (31.4)c 0.0045
Resolution 94 (23.44) 29 (51.8)b 6 (11.8)c < 0.0001
Limitation of life-sustaining measures, n (%)
Decision to withhold life-sustaining measures 124 (26.8) 18 (28.6) 16 (27.1) 0.9587
Decision to withdraw life-sustaining measures 101 (21.9) 14 (22.2) 14 (23.7) 0.9480
Decision to withhold or withdraw life-sustaining measures 154 (33.3) 21 (33.3) 20 (33.9) 0.9962
Before IMV or NIV start 1 (0.6) 0 (0.0) 1 (5.0) 0.2062
ICU mortalityd, n (%) 214 (46.3) 18 (28.6)b 34 (57.6)c 0.0043
Hospital mortalitye, n (%)
All patients 242 (52.8) 25 (39.7) 37 (62.7)c 0.0362
Patients with limitations of life-sustaining measuresf 137 (89.0) 17 (81.0) 19 (95.0) 0.3803
Abbreviations: ARDS Acute respiratory distress syndrome, IMV Patients invasively ventilated from day 1, independently of the type of support received after the
eventual extubation, NIV Patients treated exclusively with noninvasive ventilation, from day 1 to study exit, independently of outcome, NIV failure Patients initially
treated with noninvasive ventilation and subsequently intubated during the study period, Q1 First quartile, Q3 Third quartile
aChange in ARDS severity (according Berlin definition) was not evaluable for 76 immunocompromised patients (61 IMV, 7 NIV, and 8 NIV failure)
bStatistically significant different from the IMV group
cStatistically significant different from the NIV group
dMortality is defined as mortality at ICU discharge or at the 90th day in ICU after onset of acute hypoxemic respiratory failure, whichever event occurred first
eMortality is defined as mortality at hospital discharge or at the 90th day in hospital, after onset of acute hypoxemic respiratory failure, whichever event
occurred first
fMortality assessed in patients with a decision to withhold or withdraw life-sustaining measures
Note: Bold p values represent a statistically significant difference among the three groups
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The actual advantage of ICU admission of immuno-
compromised patients remains debated [3, 4, 10, 29, 30].
Our results demonstrate that almost 50% of immuno-
compromised patients with ARDS survive to hospital
discharge, and this may support the decision to offer
them at least an “ICU trial” [31]. Interestingly, our data
show that once immunocompromised patients are intu-
bated and invasively ventilated, they are managed very
similarly to the general ARDS population with regard to
ventilator settings and use of adjunctive therapies. As an
example, the use of advanced “rescue” treatments (such
as prone positioning and even extracorporeal membrane
oxygenation) was similar between immunocompromised
and control patients.
Two important questions on the optimal ventilatory
management of AHRF in immunocompromised patients
remain unanswered. First, is NIV the optimal first-line
ventilatory support? Two randomized controlled trials
conducted almost 20 years ago showed that NIV, com-
pared with standard oxygen therapy, significantly re-
duces the rate of intubation and mortality [16, 17], but
these findings have not been confirmed in more recent
studies. A recent randomized trial on 374 immunocom-
promised patients with AHRF did not find any benefit of
NIV over standard oxygen therapy [18]. Similarly, a post
hoc analysis on immunocompromised patients enrolled
in a large randomized trial comparing different noninva-
sive oxygenation strategies showed that first-line NIV
was associated with the highest risk of intubation and
mortality compared with standard oxygen and high-flow
nasal cannula (HFNC) oxygen [21]. In our study, 20.9%
of immunocompromised patients received NIV as
first-line ventilatory approach compared with 15.9% of
controls, and the multivariable analysis revealed that im-
munodeficiency was independently associated with the
use of NIV. This frequency of use of NIV equals exactly
that reported by Gristina in a large population of pa-
tients with hematologic malignancies admitted to ICU in
the years 2002–2006 [26]. In Azoulay’s study, the global
rate of NIV application was 38.6%, but it decreased over
the years, dropping to 26% in the period 2006–2011
[28]. In our study, patients treated exclusively with NIV
had significantly lower mortality than patients requiring in-
vasive ventilation. Of note, the majority of NIV patients
who died had a decision of limitation of life-sustaining mea-
sures. Importantly, whereas ARDS severity was not different
among ventilation subgroups, NIV patients had a markedly
lower nonpulmonary SOFA score (Additional file 2:
Table S1), indicating that patients with more severe organ
failures were more frequently treated with invasive ventila-
tory support. However, the multivariable regression ana-
lysis did not identify the need for invasive ventilation as an
independent predictor of death. This represents a major
difference with Azoulay’s study, where IMV (especially
after failure of NIV) was a strong predictor of poor out-
come [28]. Again, this can be explained at least in part by
considering that Azoulay’s study included patients from
the year 1990, when the techniques of mechanical ventila-
tion were completely different and protective ventilation
was certainly not the standard of care.
The impact of NIV failure on patients’ outcomes is the
second important issue. We observed a significantly
higher incidence of NIV failure in immunocompromised
patients than in controls, in keeping with the observa-
tion of Thille that a diagnosis of active cancer is inde-
pendently associated with NIV failure [32]. In our study,
in 48% of immunocompromised patients initially treated
with NIV, NIV failed, and they had a significantly worse
mortality than patients successfully managed with NIV,
as previously reported by Bellani et al. [23]. Less ex-
pected was the finding that mortality of NIV failure pa-
tients was not different from that of the patients
managed ab initio with IMV. However, two factors may
limit the relevance of this observation: the relatively low
number of patients in the NIV failure subgroup and the
lack of information on the actual duration (i.e., in hours
rather than days) of the NIV period before intubation,
which would be important to know in the light of litera-
ture data showing that delaying endotracheal intubation
after a prolonged NIV trial may negatively impact pa-
tient survival [19, 20]. In line with our data, Demoule et
al. recently observed a progressive reduction of the im-
pact of NIV failure on mortality in a large population of
AHRF patients also including immunocompromised
subjects [33]. Taken together, these data probably sug-
gest that better patient selection, earlier recognition of
failure, and improvement in ventilation techniques may
have contributed to limit the impact of NIV failure on
mortality in recent years.
Limitations
The present study has several limitations. First, it is a
post hoc analysis of a prospective multicenter observa-
tional trial, and unknown confounders associated with
the subgroup analysis may bias the results. Although the
data were prospectively collected from a high number of
centers from 50 countries, different approaches to clin-
ical decisions from different centers (e.g., decisions on
withholding or withdrawing of life-sustaining measures)
may have influenced the outcomes. Second, the criteria
used to define the immunocompromised cohort were
quite heterogeneous. It was impossible to stratify the pa-
tients according to the prognosis of baseline disease and
to the severity of immune deficiency. Indeed, causes of
immunosuppression, other than malignancies, were not
specified in nearly 40% of the whole cohort of immuno-
compromised patients. Moreover, in patients with can-
cer, no information was available on the type of cancer,
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its staging, and the nature and timing of anticancer
treatments. This lack of information, related to the
LUNG SAFE original CRF, should be considered a major
limitation because the outcome of immunocompromised
patients is strictly dependent on the type of underlying
diseases and associated therapeutic approach. All these
factors may limit the generalizability of our findings.
Third, to limit the burden on investigators, data were
collected once daily only, and information on the actual
hours of duration of ventilatory treatments was not
available. This is particularly relevant for patients treated
with NIV because the precise duration of NIV before
the eventual intubation might be important to under-
stand the impact of NIV failure on outcome [24]. Fourth,
no information were provided on the type of interface
used for NIV, a factor that can affect the outcome of
NIV [34]. Moreover, patients treated with HFNC oxygen
therapy were excluded from the LUNG SAFE study be-
cause they did not fulfill criteria for ARDS. Fifth, the
LUNG SAFE study was conducted in a very large num-
ber of ICUs with different experience in the treatment of
ARDS. This may be particularly relevant for immuno-
compromised patients, who may have better outcomes if
treated in highly experienced, dedicated units [35].
Conclusions
Immunocompromised patients represent an important
proportion of ARDS patients in the ICU. Compared with
immunocompetent subjects, they had higher mortality,
regardless of ARDS severity, and a higher frequency
of limitation of life-sustaining measures. Nonetheless,
nearly half of these patients survive to hospital discharge.
They were more likely to receive NIV as the first ventilator
strategy, and those who did not require invasive ventila-
tion had a lower mortality. Mortality of immunocom-
promised patients who failed NIV was not different from
that of patients treated ab initio with IMV. These data
should be considered in light of the nonspecific criteria
used to define the immunocompromised population and
the potentially heterogeneous approaches to clinical
decision making in the participating centers.
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Italy: Santa Maria delle Croci Hospital (Ravenna): Gianluca Zani, Maurizio
Fusari; Arcispedale Sant’Anna Ferrara (Ferrara): Savino Spadaro, Carlo A. Volta;
Ospedale Profili (Fabriano [An]): Romano Graziani, Barbara Brunettini;
Umberto I Nocera Inferiore (Nocera Inferiore Salerno): Salvatore Palmese;
Azienda Ospedaliera San Paolo – Polo Universitario, Università degli Studi di
Milano (Milan): Paolo Formenti, Michele Umbrello; Sant’Anna (San Fermo
Della Battaglia [Co]): Andrea Lombardo; Spedali Civili Brescia (Brescia):
Elisabetta Pecci, Marco Botteri; Fondazione IRCCS Ca’ Granda, Ospedale
Maggiore Policlinico (Milan): Monica Savioli, Alessandro Protti; University
Campus Bio-Medico of Rome (Rome): Alessia Mattei, Lorenzo Schiavoni;
Azienda Ospedaliera “Mellino Mellini” (Chiari [Bs]): Andrea Tinnirello, Manuel
Todeschini; Policlinico P. Giaccone, University of Palermo (Palermo): Antonino
Giarratano, Andrea Cortegiani; Niguarda Cà Granda Hospital (Milan): Sara
Sher, Anna Rossi; A.Gemelli University Hospital (Rome): Massimo M. Antonelli,
Luca M. Montini; Ospedale “Sandro Pertini” (Rome): Paolo Casalena, Sergio
Scafetti; ISMeTT IRCCS UPMC (Palermo): Giovanna Panarello, Giovanna
Occhipinti; Ospedale San Gerardo (Monza): Nicolò Patroniti, Matteo Pozzi;
Santa Maria Della Scaletta (Imola): Roberto R. Biscione, Michela M. Poli;
Humanitas Research Hospital (Rozzano): Ferdinando Raimondi, Daniela
Albiero; Ospedale Desio Azienda Ospedaliera Desio-Vimercate (Desio): Giulia
Crapelli, Eduardo Beck; Pinetagrande Private Hospital (Castelvolturno):
Vincenzo Pota, Vincenzo Schiavone; IRCCS Azienda Ospedaliera Universitaria
San Martino - IST (Genova): Alexandre Molin, Fabio Tarantino; Ospedale San
Raffaele (Milano): Giacomo Monti, Elena Frati; Ospedali Riuniti Di Foggia
(Foggia): Lucia Mirabella, Gilda Cinnella; Azienda Ospedaliera Luigi Sacco - Polo
Universitario (Milano): Tommaso Fossali, Riccardo Colombo; A.O.U. Città della
Salute e della Scienza di Torino (Turin): Pierpaolo Terragni Ilaria Pattarino;
Università degli Studi di Pavia - Fondazione IRCCS Policlinico San Matteo (Pavia):
Francesco Mojoli, Antonio Braschi; Azienda Ospedaliera Ospedale Civile
Legnano (Legnano): Erika E. Borotto; Arnas Ospedale Civico Di Cristina Benfratelli
(Palermo): Andrea N. Cracchiolo, Daniela M. Palma; Azienda Ospedaliera Della
Provincia Di Lecco - Ospedale “A. Manzoni” (Lecco): Francesco Raponi, Giuseppe
Foti; A.O. Provincia Di Lecco - Ospedale Alessandro Manzoni (Lecco): Ettore R.
Vascotto, Andrea Coppadoro; Cliniche Universitarie Sassari (Sassari): Luca Brazzi,
Leda Floris; IRCCS Policlinico San Matteo (Pavia): Giorgio A. Iotti, Aaron Venti
Japan: Yokohama City University Hospital (Yokohama): Osamu Yamaguchi,
Shunsuke Takagi; Toyooka Hospital (Toyooka City, Hyogo Prefecture): Hiroki
N. Maeyama; Chiba University Hospital (Chiba City): Eizo Watanabe, Yoshihiro
Yamaji; Okayma University Hospital (Okayama): Kazuyoshi Shimizu, Kyoko
Shiozaki; Japanese Foundation for Cancer Research, Cancer Institute Hospital,
Department of Emergency Medicine and Critical Care (Tokyo): Satoru Futami;
Ibaraki Prefectural Central Hospital (Kasama): Sekine Ryosuke; Tohoku
University Hospital (Sendai-Shi): Koji Saito, Yoshinobu Kameyama; Tokyo
Medical University Hachioji Medical Center (Hachioji, Tokyo): Keiko Ueno;
Tokushima University Hospital (Tokushima): Masayo Izawa, Nao Okuda;
Maebashi Red Cross Hospital (Gunma Maebashi): Hiroyuki Suzuki, Tomofumi
Harasawa; Urasoe General Hospital (Urasoe): Michitaka Nasu, Tadaaki Takada;
Ohta General Hospital Foundation Ohta Nishinouchi Hospital (Fukushima):
Fumihito Ito; Jichi Medical University Hospital (Shimotsuke): Shin Nunomiya,
Kansuke Koyama; Mito Kyodo General Hospital, Tsukuba University Hospital
Mito Medical Center (Mito): Toshikazu Abe; Sendai City Hospital (Sendai):
Kohkichi Andoh, Kohei Kusumoto; Ja Hiroshima General Hospital (Hatsukaichi
City, Hiroshima): Akira Hirata, Akihiro Takaba; Yokohama Rosai Hospital
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(Yokohama): Hiroyasu Kimura; Nagasaki University Hospital (Nagasaki): Shuhei
Matsumoto, Ushio Higashijima; Niigata University Medical & Dental Hospital
(Niigata): Hiroyuki Honda, Nobumasa Aoki; Mie University Hospital (Tsu, Mie):
Hiroshi Imai; Yamaguchi University Hospital (Ube, Yamaguchi): Yasuaki Ogino,
Ichiko Mizuguchi; Saiseikai Kumamoto Hospital (Kumamoto City): Kazuya
Ichikado; Shinshu University School of Medecine (Matsumoto City): Kenichi
Nitta, Katsunori Mochizuki; Kuki General Hospital (Kuki): Tomoaki Hashida;
Kyoto Medical Center (Kyoto): Hiroyuki Tanaka; Fujita Health University
(Toyoake): Tomoyuki Nakamura, Daisuke Niimi; Rakwakai Marutamachi
Hospital (Kyoto): Takeshi Ueda; Osaka University Hospital (Suita City, Osaka
Prefecture): Yozo Kashiwa, Akinori Uchiyama
Latvia: Paul Stradins Clinical University Hospital (Riga): Olegs Sabelnikovs, Peteris Oss
Lebanon: Kortbawi Hospital (Jounieh): Youssef Haddad
Malaysia: Hospital Kapit (Kapit): Kong Y. Liew
Mexico: Instituto Nacional De Cancerología, México (Mexico City): Silvio A.
Ñamendys-Silva, Yves D. Jarquin-Badiola; Hospital De Especialidades “Antonio
Fraga Mouret” Centro Medico Nacional La Raza IMSS (Mexico City): Luis A.
Sanchez-Hurtado, Saira S. Gomez-Flores; Hospital Regional 1° De Octubre
(Mexico City): Maria C. Marin, Asisclo J. Villagomez; Hospital General
Dr. Manuel Gea Gonzalez (Mexico City): Jordana S. Lemus, Jonathan M. Fierro;
Hospital General De Zona No. 1 Instituto Mexicano Del Seguro Social Tepic
Nayarit (Tepic): Mavy Ramirez Cervantes, Francisco Javier Flores Mejia; Centro
Medico Dalinde (Mexico D.F.): Dulce Dector, Dulce M. Dector; OPD Hospital Civil
De Guadalajara Hospital Juan I. Menchaca (Guadalajara): Daniel R. Gonzalez,
Claudia R. Estrella; Hospital Regional De Ciudad Madero Pemex (Ciudad Madero):
Jorge R. Sanchez- Medina, Alvaro Ramirez-Gutierrez; Centro Médico ABC (Mexico
D.F.): Fernando G. George, Janet S. Aguirre; Hospital Juarez De Mexico (Mexico
City): Juan A. Buensuseso, Manuel Poblano
Morocco: Mohammed V University, University Teaching Ibn Sina Hospital
(Rabat): Tarek Dendane, Amine Ali Zeggwagh; Hopital Militaire D’Instruction
Mohammed V (Rabat): Hicham Balkhi; Errazi (Marrakech): Mina Elkhayari,
Nacer Samkaoui; University Teaching Hospital Ibn Rushd (Casablanca):
Hanane Ezzouine, Abdellatif Benslama; Hôpital des Spécialités de Rabat (HSR)
(Rabat): Mourad Amor, Wajdi Maazouzi
The Netherlands: Tjongerschans (Heerenveen): Nedim Cimic, Oliver Beck; CWZ
(Nijmegen): Monique M. Bruns, Jeroen A. Schouten; Rijnstate Hospital
(Arnhem): Myra - Rinia, Monique Raaijmakers; Radboud UMC (Nijmegen): Leo
M. Heunks, Hellen M. Van Wezel; Maastricht University Medical Centre
(Maastricht): Serge J. Heines, Ulrich Strauch; Catharinaziekenhuis (Eindhoven):
Marc P. Buise; Academic Medical Center (Amsterdam): Fabienne D. Simonis,
Marcus J. Schultz
New Zealand: Tauranga Hospital (Tauranga): Jennifer C. Goodson, Troy S.
Browne; Wellington Hospital (Wellington): Leanlove Navarra, Anna Hunt;
Dunedin Hospital (Dunedin): Robyn A. Hutchison, Mathew B. Bailey; Auckland
City Hospital (Auckland): Lynette Newby, Colin Mcarthur; Whangarei Base
Hospital (Whangarei): Michael Kalkoff, Alex Mcleod; North Shore Hospital
(Auckland): Jonathan Casement, Danielle J. Hacking
Norway: Ålesund Hospital (Ålesund): Finn H. Andersen, Merete S. Dolva; Oslo
University Hospital Rikshospitalet Medical Centre (Oslo): Jon H. Laake,
Andreas Barratt-Due; Stavanger University Hospital (Stavanger): Kim Andre L.
Noremark, Eldar Søreide; Haukeland University Hospital (Bergen): Brit Å. Sjøbø,
Anne B. Guttormsen
Peru: Hospital Nacional Edgardo Rebagliati Martins (Lima): Hector H. Leon
Yoshido; Clínica Ricardo Palma (Lima): Ronald Zumaran Aguilar, Fredy A.
Montes Oscanoa
The Philippines: The Medical City (Pasig): Alain U. Alisasis, Joanne B. Robles;
Chong Hua Hospital (Cebu): Rossini Abbie B. Pasanting-Lim, Beatriz C. Tan
Poland: Warsaw University Hospital (Warsaw): Pawel Andruszkiewicz, Karina
Jakubowska
Portugal: Centro Hospitalar da Cova da Beira (Covilhã): Cristina M. Coxo;
Hospital Santa Maria, Centro Hospitalar Lisboa Norte (Lisboa): António M.
Alvarez, Bruno S. Oliveira; Centro Hospitalar Trás-os-Montes e Alto Douro - Hospital
de S. Pedro - Vila Real (Vila Real): Gustavo M. Montanha, Nelson C. Barros; Hospital
Beatriz Ângelo (Loures): Carlos S. Pereira, António M. Messias; Hospital de Santa
Maria (Lisboa): Jorge M. Monteiro; Centro Hospitalar Médio Tejo - Hospital De
Abrantes (Abrantes): Ana M. Araujo, Nuno T. Catorze; Instituto Português de
Oncologia de Lisboa (Lisboa): Susan M. Marum, Maria J. Bouw; Hospital Garcia De
Orta (Almada): Rui M. Gomes, Vania A. Brito; Centro Hospitalar do Algarve (Faro):
Silvia Castro, Joana M. Estilita; HPP Hospital De Cascais (Alcabideche):
Filipa M. Barros; Hospital Prof. Doutor Fernando Fonseca Epe (Amadora):
Isabel M. Serra, Aurelia.
Romania: Fundeni Clinical Institute (Bucharest): Dana R. Tomescu, Alexandra
Marcu; Emergency Clinical County Hospital Timisoara (Timisoara): Ovidiu H.
Bedreag, Marius Papurica; Elias University Emergency Hospital (Bucharest):
Dan E. Corneci, Silvius Ioan Negoita
Russian Federation: University Hospital (Kemerovo): Evgeny Grigoriev;
Krasnoyarsk Regional Hospital, Krasnoyarsk State Medical University
(Krasnoyarsk): Alexey I. Gritsan, Andrey A. Gazenkampf
Saudi Arabia: GICU of PSMMC (Riyadh): Ghaleb Almekhlafi, Mohamad M.
Albarrak; SICU of PSMMC (Riyadh): Ghanem M. Mustafa; King Faisal Hospital
and Research Center (Riyadh): Khalid A. Maghrabi, Nawal Salahuddin; King
Fahad Hospital (Baha): Tharwat M. Aisa; King Abdulaziz Medical City (Riyadh):
Ahmed S. Al Jabbary, Edgardo Tabhan; King Abdulaziz Medical City (Riyadh):
Yaseen M. Arabi; King Abdulaziz Medical City (Riyadh): Yaseen M. Arabi, Olivia
A. Trinidad; King Abdulaziz Medical City (Riyadh): Hasan M. Al Dorzi, Edgardo
E. Tabhan
South Africa: Charlotte Maxeke Johannesburg Academic Hospital
(Johannesburg): Stefan Bolon, Oliver Smith
Spain: Hospital Sant Pau (Barcelona): Jordi Mancebo, Hernan Aguirre-Bermeo;
Hospital Universitari Bellvitge (L’Hospitalet de Llobregat (Barcelona)): Juan C.
Lopez-Delgado, Francisco Esteve; Hospital Son Llatzer (Palma de Mallorca):
Gemma Rialp, Catalina Forteza; Sabadell Hospital, CIBER Enfermedades
Respiratorias (Sabadell): Candelaria de Haro, Antonio Artigas; Hospital
Universitario Central de Asturias (Oviedo): Guillermo M. Albaiceta, Sara de
Cima- Iglesias; Complejo Hospitalario Universitario de A Coruña (A Coruña):
Leticia Seoane-Quiroga, Alexandra Ceniceros-Barros; Hospital Universitario
Miguel Servet (Zaragoza): Antonio L. Ruiz- Aguilar, Luis M. Claraco-Vega;
Morales Meseguer University Hospital (Murcia): Juan Alfonso Soler, Maria del
Carmen Lorente; Hospital Universitario del Henares (Coslada): Cecilia Hermosa,
Federico Gordo; Complejo Asistencial de Palencia. Hospital Rio Carrión
(Palencia): Miryam Prieto-González, Juan B. López-Messa; Fundación Jiménez
Díaz (Madrid): Manuel P. Perez, Cesar P. Perez; Hospital Clínico Universitario
Lozano Blesa (Zaragoza): Raquel Montoiro Allue; Hospital Verge de la Cinta
(Tortosa): Ferran Roche-Campo, Marco Ibañez-Santacruz; Hospital Universitario
12 de Octubre (Madrid): Susana Temprano; Hospital Universitario Príncipe de
Asturias (Alcalá de Henares, Madrid): Maria C. Pintado, Raul de Pablo; Hospital
Universitari Germans Trias i Pujol (Badalona): Pilar Ricart Aroa Gómez; Hospital
Universitario Arnau de Vilanova de Lleida (Lleida): Silvia Rodriguez Ruiz, Silvia
Iglesias Moles; Consorci Sanitari de Terrassa - Hospital de Terrassa (Barcelona):
Maria Teresa Jurado, Alfons Arizmendi; Hospital Universitari Mútua Terrassa
(Terrassa): Enrique A. Piacentini; Hospital Universitario de Móstoles (Mostoles):
Nieves Franco, Teresa Honrubia; Complejo Asistencial de Salamanca (Salamanca):
Meisy Perez Cheng, Elena Perez Losada; Hospital General Universitario de Ciudad
Real (Ciudad Real): Javier Blanco, Luis J. Yuste; Torrecardenas (Almeria): Cecilia
Carbayo-Gorriz, Francisca G. Cazorla-Barranquero; Hospital Universitario Donostia
(San Sebastian): Javier G. Alonso, Rosa S. Alda; Hospital Universitario de Torrejón
(Madrid): Ángela Algaba, Gonzalo Navarro; Hospital Universitario de La Princesa
(Madrid): Enrique Cereijo, Esther Diaz-Rodriguez; Hospital Universitario Lucus
Augusti (Lugo): Diego Pastor Marcos, Laura Alvarez Montero; Hospital
Universitario Santa Lucia (Cartagena): Luis Herrera Para, Roberto Jimenez Sanchez;
Hospital Universitario Severo Ochoa, Leganes (Madrid): Miguel Angel Blasco
Navalpotro, Ricardo Diaz Abad; University Hospital of Nuestra Señora de
Candelaria (Santa Cruz de Tenerife): Raquel Montiel González, Dácil Parrilla Toribio;
Hospital Universitario Marques de Valdecilla (Santander): Alejandro G. Castro,
Maria Jose D. Artiga; Hospital Infanta Cristina (Parla, Madrid): Oscar Penuelas;
Hospital General de Catalunya (Sant Cugat Del Valles): Tomas P. Roser, Moreno F.
Olga; San Pedro de Alcántara (Cáceres): Elena Gallego Curto, Rocío Manzano
Sánchez; Sant Joan de Reus (Reus): Vallverdu P. Imma, Garcia M. Elisabet; Hospital
Joan XXIII (Tarragona): Laura Claverias, Monica Magret; Hospital Universitario de
Getafe (Madrid): Ana M. Pellicer, Lucia L. Rodriguez; Hospital Universitario Río
Hortega (Valladolid): Jesús Sánchez-Ballesteros, Ángela González-Salamanca;
Hospital Arquitecto Marcide (Ferrol, A Coruña): Antonio G. Jimenez, Francisco P.
Huerta; Hospital General Universitario Gregorio Marañón (Madrid): Juan Carlos J.
Sotillo Diaz, Esther Bermejo Lopez; Hospital General de Segovia (Segovia): David
D. Llinares Moya, Alec A. Tallet Alfonso; Hospital General Universitario Reina Sofia
(Murcia): Palazon Sanchez Eugenio Luis, Palazon Sanchez Cesar; Complejo
Hospitalario Universitario de Albacete (Albacete): Sánchez I. Rafael, Corcoles G.
Virgilio; Hospital Infanta Elena (Valdemoro): Noelia N. Recio
Sweden: Sahlgrenska University Hospital (Gothenburg): Richard O. Adamsson,
Christian C. Rylander; Karolinska University Hospital (Stockholm): Bernhard
Holzgraefe, Lars M. Broman; Akademiska Sjukhuset Uppsala (Uppsala): Joanna
Wessbergh, Linnea Persson; Vrinnevisjukhuset (Norrköping): Fredrik Schiöler,
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Hans Kedelv; Linkoping University Hospital (Linköping): Anna Oscarsson
Tibblin, Henrik Appelberg; Skellefteå Lasarett (Skellefteå): Lars Hedlund, Johan
Helleberg; Karolinska University Hospital Solna (Stockholm): Karin E. Eriksson,
Rita Glietsch; Umeå University Hospital (Umeå): Niklas Larsson, Ingela Nygren;
Danderyd Hospital (Stockholm): Silvia L. Nunes, Anna-Karin Morin; Lund Uni-
versity Hospital (Lund): Thomas Kander, Anne Adolfsson
Switzerland: CHUV (Centre hospitalier universitaire vaudois) (Lausanne): Lise
Piquilloud; Hôpital neuchâtelois - La Chaux-de-Fonds (La Chaux-de-Fonds):
Hervé O. Zender, Corinne Leemann-Refondini
Tunisia: Hopital Taher Sfar Mahdia (Mahdia): Souheil Elatrous; University
Hospital Farhat Hached Sousse (Sousse): Slaheddine Bouchoucha, Imed
Chouchene; CHU F. Bourguiba (Monastir): Islem Ouanes; Mongi Slim
University Hospital, La Marsa (La Marsa): Asma Ben Souissi, Salma Kamoun
Turkey: Cerrahpasa Medical Faculty Emergency Intensive Care Unit (Istanbul):
Oktay Demirkiran; Cerrahpasa Medical Faculty Sadi Sun Intensive Care Unit
(Istanbul): Mustafa Aker, Emre Erbabacan; Uludag University Medical Faculty
(Bursa): Ilkay Ceylan, Nermin Kelebek Girgin; Ankara University Faculty of
Medicine, Reanimation, Level 3 ICU (Ankara): Menekse Ozcelik, Necmettin
Ünal; Ankara University Faculty of Medicine, Level 2 ICU-Postoperative ICU
(Ankara): Basak Ceyda Meco; Istanbul Kartal Eğitim ve Araştırma Hastanesi
(Istanbul): Onat O. Akyol, Suleyman S. Derman
United Kingdom: Papworth Hospital (Cambridge): Barry Kennedy, Ken Parhar;
Royal Glamorgan Hospital (Llantrisant): Latha Srinivasa; Royal Victoria Hospital-
Belfast (Belfast): Lia McNamee, Danny McAuley; Jack Steinberg Critical Care Unit,
King’s College London (London): Phil Hopkins, Clare Mellis; Frank Stansil Critical
Care Unit, King’s College Hospital (London): Vivek Kakar; Liver ICU of King’s
College London (London): Dan Hadfield; Christine Brown Critical Care Unit,
King’s College London (London): Andre Vercueil; West Suffolk Hospital (Bury
St. Edmunds): Kaushik Bhowmick, Sally K. Humphreys; Craigavon Area Hospital
(Portadown): Andrew Ferguson, Raymond Mckee; Barts Health NHS Trust, Whipps
Cross Hospital (Leytonstone): Ashok S. Raj, Danielle A. Fawkes; Kettering General
Hospital, Foundation NHS Trust (Northamptonshire): Philip Watt, Linda Twohey;
Barnet General Hospital (Barnet): Rajeev R. JhaMatthew Thomas, Alex Morton,
Varsha Kadaba; Rotherham General Hospital (Rotherham): Mark J. Smith,
Anil P. Hormis; City Hospital (Birmingham): Santhana G. Kannan, Miriam Namih;
Poole Hospital NHS Foundation Trust (Poole): Henrik Reschreiter, Julie
Camsooksai; Weston General Hospital (Weston-Super-Mare): Alek Kumar, Szabolcs
Rugonfalvi; Antrim Area Hospital (Antrim): Christopher Nutt, Orla Oneill; Aintree
University Hospital (Liverpool): Colette Seasman, Ged Dempsey; Northern General
Hospital (Sheffield): Christopher J. Scott, Helen E. Ellis; John Radcliffe Hospital
(Oxford): Stuart Mckechnie, Paula J. Hutton; St. George’s Hospital (London):
Nora N. Di Tomasso, Michela N. Vitale; Hillingdon Hospital (Uxbridge): Ruth Griffin,
Michael N. Dean; The Royal Bournemouth & Christchurch NHS Foundation Trust
(Bournemouth, Dorset): Julius H. Cranshaw, Emma L. Willett; Severe Respiratory
Failure Service, Guy’s and St. Thomas’ NHS Foundation Trust (London): Nicholas
Ioannou; Whittington Hospital (London): Sarah Gillis; Wexham Park Hospital
(Slough): Peter Csabi; Western General Hospital (Edinburgh): Rosaleen Macfadyen,
Heidi Dawson; Royal Preston Hospital (Preston): Pieter D. Preez, Alexandra
J. Williams; Brighton and Sussex University Hospitals NHS Trust (Brighton): Owen
Boyd, Laura Ortiz-Ruiz de Gordoa; East and North Herts NHS Trust (Stevenage):
Jon Bramall, Sophie Symmonds; Barnsley Hospital (Barnsley): Simon K. Chau,
Tim Wenham; Prince Charles Hospital (Merthyr Tydfil): Tamas Szakmany, Piroska
Toth-Tarsoly; University Hospital of South Manchester NHS Foundation Trust
(Manchester): Katie H. Mccalman, Peter Alexander; Harrogate District Hospital
(Harrogate): Lorraine Stephenson, Thomas Collyer; East and North Herts NHS
Trust (Welwyn Garden City): Rhiannon Chapman, Raphael Cooper; Western
Infirmary (Glasgow): Russell M. Allan, Malcolm Sim; Dumfries and Galloway Royal
Infirmary (Dumfries): David W. Wrathall, Donald A. Irvine; Charing Cross Hospital
(London): Kim S. Zantua, John C. Adams; Worcestershire Royal Hospital
(Worcester): Andrew J. Burtenshaw, Gareth P. Sellors; Royal Liverpool University
Hospital (Liverpool): Ingeborg D. Welters, Karen E. Williams; Royal Alexandra
Hospital (Glasgow): Robert J. Hessell, Matthew G. Oldroyd; Morriston Hospital
(Swansea): Ceri E. Battle, Suresh Pillai; Frimley Park Hospita (Frimley): Istvan - Kajtor,
Mageswaran - Sivashanmugavel; Altnagelvin Hospital (Derry): Sinead C. Okane,
Adrian Donnelly; Buckinghamshire Healthcare NHS Trust (High Wycombe,
Buckinghamshire): Aniko D. Frigyik, Jon P. Careless; Milton Keynes Hospital (Milton
Keynes): Martin M. May, Richard Stewart; Ulster Hospital (Belfast): T. John Trinder,
Samantha J. Hagan; University Hospital of Wales (Cardiff): Matt P. Wise, Jade M. Cole;
Freeman Hospital (Newcastle Upon Tyne): Caroline C. MacFie, Anna T. Dowling
Uruguay: Hospital Español (Montevideo): Javier Hurtado, Nicolás Nin; Cudam
(Montevideo): Javier Hurtado; Sanatorio Mautone (Maldonado): Edgardo
Nuñez; Sanatorio Americano (Montevideo): Gustavo Pittini, Ruben Rodriguez;
Hospital de Clínicas (Montevideo): María C Imperio, Cristina Santos; Circulo
Católico Obreros Uruguay - Sanatorio Juan Pablo II (Montevideo): Ana G.
França, Alejandro Ebeid; CASMU (Montevideo): Alberto Deicas, Carolina Serra
United States: St. Louis University Hospital (St. Louis, MO): Aditya Uppalapati,
Ghassan Kamel; Beth Israel Deaconess Medical Center (Boston, MA): Valerie
M. Banner-Goodspeed, Jeremy R. Beitler; Memorial Medical Center
(Springfield, IL): Satyanarayana Reddy Mukkera, Shreedhar Kulkarni;
Massachusetts General Hospital (Boston, MA): Jarone Lee, Tomaz Mesar;
University of Cincinnati Medical Center (Cincinnati, OH): John O Shinn Iii,
Dina - Gomaa; Massachusetts General Hospital (Boston, MA): Christopher
Tainter, Jarone Lee; Massachusetts General Hospital (Boston, MA): Tomaz
Mesar, Jarone Lee; R. Adams Cowley Shock Trauma Center, University of
Maryland Medical Center (Baltimore, MD): Dale J. Yeatts, Jessica Warren;
Intermountain Medical Center (Murray, UT): Michael J. Lanspa, Russel R. Miller,
Colin K. Grissom, Samuel M. Brown; Mayo Clinic (Rochester, MN): Philippe R.
Bauer; North Shore Medical Center (Salem, MA): Ryan J. Gosselin, Barrett T.
Kitch; Albany Medical Center (Albany, NY): Jason E. Cohen, Scott H. Beegle;
John H. Stoger Hospital of Cook County (Chicago, IL): Renaud M. Gueret,
Aiman Tulaimat; Albany Medical Center (Albany, NY); Shazia Choudry;
University of Alabama at Birmingham (UAB) (Birmingham, AL): William Stigler,
Hitesh Batra; Duke University Hospital (Durham, NC): Nidhi G. Huff; Iowa
Methodist Medical Center (Des Moines, IA): Keith D. Lamb, Trevor W. Oetting;
Surgical & Neurosciences Intensive Care Unit of the University of Iowa
Hospitals and Clinics (Iowa City, IA): Nicholas M. Mohr, Claine Judy; Medical
Center of Louisiana at New Orleans (New Orleans, LA): Shigeki Saito, Fayez M.
Kheir; Tulane University (New Orleans, LA): Fayez Kheir; Critical Care Unit of
the University of Iowa Hospitals and Clinics (Iowa City, IA): Adam B.
Schlichting, Angela Delsing; University of California, San Diego Medical
Center (San Diego, CA): Daniel R. Crouch, Mary Elmasri; UC San Diego
Thornton Hospital (La Jolla, CA): Daniel R. Crouch, Dina Ismail; University
Hospital (Cincinnati, OH): Kyle R. Dreyer, Thomas C. Blakeman; University
Hospital (Cincinnati, OH): Kyle R. Dreyer, Dina Gomaa; Tower 3B Medical ICU
of Brigham and Women’s Hospital (Boston, MA): Rebecca M. Baron, Carolina
Quintana Grijalba; Tower 8C Burn/Trauma ICU of Brigham and Women’s
Hospital (Boston, MA): Peter C. Hou; Tower 8D Surgical ICU of Brigham and
Women’s Hospital (Boston, MA): Raghu Seethala; Tower 9C Neurosurgical ICU
of Brigham and Women’s Hospital (Boston, MA): Imo Aisiku; Tower 9D
Neurological ICU of Brigham and Women’s Hospital (Boston, MA): Galen
Henderson; Tower 11C Thoracic ICU of Brigham and Women’s Hospital
(Boston, MA): Gyorgy Frendl; Carl J. and Ruth Shapiro Cardiovascular Center,
Brigham and Women’s Hospital (Boston, MA): Sen-Kuang Hou, Robert L. Owens,
Ashley Schomer
Serbia: Clinical Center of Serbia (Belgrade): Vesna Bumbasirevic, Bojan
Jovanovic; Military Medical Academy (Belgrade): Maja Surbatovic, Milic Veljovic
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